Steven A. Pergam, MD, MPH
Associate Professor
Department of Medicine, Division of Allergy & Infectious Diseases
Adjunct Associate Professor
Department of Epidemiology, School of Public Health
Medical Director of Infection Prevention, Seattle Cancer Care Alliance
Associate Member, Vaccine & Infectious Disease, Fred Hutchinson Cancer Research Center
Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center

Faculty Information


Dr. Pergam's research focuses on the prevention of infections in patients with cancer, transplant recipients, and other immunocompromised populations. He focuses on the immunogenetics of innate responses to Cytomegalovirus in hematopoietic cell transplant recipients. Current studies include the evaluation of natural killer associated KIR and CMV outcomes post-transplant. He has research programs that are currently evaluating the use of viral kinetics and advanced diagnostics to improve diagnosis of CMV complications. Dr. Pergam also has an interest in the epidemiology and prevention of viral infections in cord blood transplant recipients and other high-risk HCT populations.

As the Director of Infection Control, Dr. Pergam is actively involved in the development of new infection control strategies and educational programs. He has active research projects that aim to better understand the epidemiology of nosocomial bacterial infections and respiratory viruses in cancer patients.

Education & Training: 
University of Nebraska School of Medicine
Omaha NE
MPH, Epidemiology
University of Washington, School of Public Health
Seattle WA
University of New Mexico
Albuquerque NM
Fellowship in Infectious Diseases
University of Washington
Seattle WA
Alpha Omega Alpha, Clinical Excellence Award
William Hardy Teaching Award, Internal Medicine Attending of the Year University of New Mexico, Albuquerque, NM
Infectious Diseases Society of America Fellows Travel Award
Elected to Fellow, Infectious Disease Society of America (FIDSA)
(206) 667-7126
Mailing Address: 

Fred Hutchinson Cancer Research Center

1100 Fairview Ave. N

Box 358080

Seattle, WA 98109


Pergam SA, Xie H, Sandhu R, et al. Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients. Biol Blood Marrow Transplant. 2012; 18(9):1391-400. 
• PubMed Abstract

Milano F, Pergam SA, Xie H, et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood. 2011; 118(20):5689-96.
• PubMed Abstract

Pergam SA, Forsberg CW, Boeckh MJ, et al. (2011). Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis. 2011; 13(1);15-23.
• PubMed Abstract

Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010; 363(22):2091-101.
• PubMed Abstract

Travi G, Pergam SA, Xie H, et al. The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation. Clin Infect Dis. 2009; 49(11):e120-3.
• PubMed Abstract